1.0Allphase Pharma Consulting, LLChttps://allphasepharma.com/dirHaraldhttps://allphasepharma.com/dir/author/haraldeva/rich600338<blockquote class="wp-embedded-content" data-secret="hae4f81HdV"><a href="https://allphasepharma.com/dir/2017/01/24/3100/kill-mocking-bug-cre-crab-variety/">To Kill A Mocking Bug – of the CRKP or CRAB Variety</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://allphasepharma.com/dir/2017/01/24/3100/kill-mocking-bug-cre-crab-variety/embed/#?secret=hae4f81HdV" width="600" height="338" title="“To Kill A Mocking Bug – of the CRKP or CRAB Variety” — Allphase Pharma Consulting, LLC" data-secret="hae4f81HdV" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script> /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); //# sourceURL=https://allphasepharma.com/dir/wp-includes/js/wp-embed.min.js </script> https://i0.wp.com/allphasepharma.com/dir/wp-content/uploads/2017/01/Mero-slider.jpg?fit=640%2C180&ssl=1640180Meropenem stands out as an antibiotic to be used first in ESBL and MDR infections, given its efficacy profile and safety record (see earlier blog). It also would seem to be appropriate to use relatively high doses or prolonged infusion times – or both – to improve T>MIC for the Continue reading →